Most actively traded companies on the TSX, TSX Venture Exchange markets

TORONTO – Some of the most active companies traded Friday on the Toronto Stock Exchange and the TSX Venture Exchange:

Toronto Stock Exchange (13,478.34 up 3.01 points):

Eastern Platinum Ltd. (TSX:ELR). Miner. Up a penny, or 16.67 per cent, at seven cents on 38.81 million shares.

Pretium Resources Inc. (TSX:PVG). Miner. Up $2.45, or 79.55 per cent, at $5.53 on 4.94 million shares. The Vancouver-based company announced that a bulk ore sample at its Valley of Kings project in British Columbia had surpassed its target of 4,000 ounces of gold. Pretium said 4,215 ounces had been produced from 8,090 dry tonnes excavated at the site.

Bombardier Inc. (TSX:BBD.B). Plane and train maker. Up four cents, or 0.85 per cent, at $4.72 on 4.70 million shares.

Colossus Minerals Inc. (TSX:CSI). Miner. Down a penny, or 5.88 per cent, at 16 cents on 4.44 million shares.

Manulife Financial Corp. (TSX:MFC). Insurer. Up 26 cents, or 1.29 per cent, at $20.37 on 4.15 million shares.

Toronto Venture Exchange (932.15 up 5.43 points):

Africa Hydrocarbons Inc. (TSXV:NFK). Oil and gas. Down 15.5 cents, or 63.27 per cent, at nine cents on 19.58 million shares.

DualEx Energy International Inc. (TSXV:DXE). Oil and gas. Down 20 cents, or 63.49 per cent, at 11.5 cents on 10.65 million shares.

Companies reporting major news:

CCL Industries Inc. (TSX:CCL.B). Label and packaging. Up 29 cents, or 0.36 per cent, at $81.64 on 17,247 shares. The company announced it is closing its aerosol container plant in Penetanguishene, Ont., affecting 170 people. It was unclear how many of the employees might be able to find work elsewhere with the company. Production will be moved to Mexico and the United States.

Shoppers Drug Mart (TSX:SC). Retail drugstore chain. Down 19 cents, or 0.32 per cent, at $58.92 on 496,803 shares. The Supreme Court of Canada upheld Ontario rules banning big pharmacies from selling their own private-label generic drugs, saying the province’s 2010 decision to ban the practice was consistent with its efforts to ensure transparent drug pricing. The company and Rexall challenged the province because they wanted to be able to sell their own lower-priced generic versions of big-name drugs.